ACET

SEC source: 0001209191-22-057005 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,209

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-22-057004 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 53,424

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $20.00 to $20.27, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-057004 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,469

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $21.00 to $21.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request.

SEC source: 0001209191-22-056193 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 83,424

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $19.00 to $19.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request.

F3 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-055828 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 113,424

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.25, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request.

F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-055828 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,237

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-054261 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,176

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.01 to $16.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 8

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 53,424

F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 7

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,045

SEC source: 0001209191-22-053659 · doc4.xml · nonDerivative · entry 3

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,243

F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-22-053659 · doc4.xml · derivative · entry 4

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,612

Underlying: Common Stock · 3,388 shares

Expires 2031-10-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · derivative.exercise_date: A total of 60,000 shares subject to an employee stock option were granted to the Reporting Person on October 12, 2021. 25% of the shares subject to the stock option vested and became exercisable on October 12, 2022, with the remainder vesting in equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001209191-22-053659 · doc4.xml · nonDerivative · entry 2

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,176

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-22-053659 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-22-052383 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,424

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-22-052380 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,816

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-22-052376 · doc4.xml · nonDerivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,468

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-22-052378 · doc4.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,451

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 6

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 26,712

F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 5

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,757

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,469

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-050372 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,737

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 139,689

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.05, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 26,712

F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,757

SEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 143,060

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $16.50 to $16.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 66,747

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $16.50 to $16.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request.

F3 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,712

SEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

F3 · balance_after: The Reporting Person was issued 240,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 96,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 144,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 48,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-044903 · doc4.xml · nonDerivative · entry 2

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,434

SEC source: 0001209191-22-044903 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,967

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 12, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 13, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 12, 2022 and the second tranche vesting on October 12, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-044904 · doc4.xml · nonDerivative · entry 2

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,384

SEC source: 0001209191-22-044904 · doc4.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,917

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-044901 · doc4.xml · nonDerivative · entry 2

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,401

SEC source: 0001209191-22-044901 · doc4.xml · nonDerivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,934

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-044902 · doc4.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,912

SEC source: 0001209191-22-044902 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,608

F1 · balance_after: The Reporting Person was issued 80,000 Restricted Stock Units ("RSUs") on October 1, 2021, as previously reported on a Form 4 filed by the Reporting Person on October 5, 2021. Each RSU represents a contingent right to receive one share of common stock. A total of 32,000 of the RSUs shall vest in two (2) annual installments of 20% of the shares vesting, with the first tranche vesting on October 1, 2022 and the second tranche vesting on October 1, 2023. A total of 48,000 of the RSUs shall vest upon achievements of specific milestones outlined in the Reporting Person's Restricted Stock Unit Agreement. On August 4, 2022, upon the occurrence of the third performance milestone, 16,000 of the RSUs vested. The RSUs may be settled only by delivering shares of common stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-044646 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,967

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-22-044182 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,935

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.33 to $16.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 143,260

F1 · kind: Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration.

F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-22-044905 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

F1 · kind: Represents the transfer of shares held by the Reporting Person to The C. Schor IRRV Trust for no consideration.

SEC source: 0001209191-22-041499 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,903

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · balance_after: Includes 1,363 shares purchased under the Issuer's Amended and Restated 2018 Employee Stock Purchase Plan on June 30, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).

SEC source: 0001209191-22-034097 · doc4.xml · derivative · entry 1

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034103 · doc4.xml · derivative · entry 1

GORDON CARL L · CIK 0001282930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034092 · doc4.xml · derivative · entry 1

Sanna Bastiano · CIK 0001829069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034088 · doc4.xml · derivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034082 · doc4.xml · derivative · entry 1

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034079 · doc4.xml · derivative · entry 1

DUBIN STEVE · CIK 0001265123 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-034072 · doc4.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.